| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Alignment Healthcare, Inc. Common Stock$18.61
-2.29 (-12.52%)
Market Cap
4.19 B
EPS
0.00
P/E Ratio
-5,000 $
Value Trade
142.58 M
SEC Financials
Q1 2026Dilution Risk
Revenue
1.24 B
Operating CF
128.68 M
Total Assets
1.26 B
Total Liabilities
1.05 B
Equity
206.88 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
726.29 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 30, 2026
Overview
Volume
4.06 M
52 Week Range
11.63 - 23.87
% held by Insiders
5.29 %
% held by Institutions
104.03 %
Enterprise Value
4.53 B
Total Shares
206.78 M
Short %
12.67 %
Float Shares
183.41 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ALHC
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ALHC Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-02-19 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2027-02-19 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2027-02-19 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-ALHC
Jul 30, 2026▼ -12.5%today
Alignment Healthcare Reports Second Quarter 2026 Results, Surpassing High End of Guidance Across All Key Metrics
Alignment Healthcare reported strong financial results for Q2 2026, with total revenue reaching $1.3 billion, marking a 31.6% increase year-over-year. The company also saw a significant growth in Medicare Advantage membership, which rose by 31.5% to approximately 294,100 members. Additionally, the company raised its full-year guidance across key metrics, indicating a positive outlook for the remainder of the year.
Read more →-ALHC
Jul 9, 2026Alignment Healthcare to Announce Second Quarter 2026 Financial Results and Host Conference Call Thursday, July 30, 2026
Alignment Healthcare, Inc. (NASDAQ: ALHC) will announce its second quarter 2026 financial results on July 30, 2026, after market close. Following the announcement, a conference call will be held at 5 p.m. EDT to discuss the results. The company emphasizes its mission to provide high-quality, low-cost care for Medicare Advantage members.
Read more →-ALHC
Jun 2, 2026Alignment Healthcare Shows How Earlier, Coordinated Care Leads to Better Health and Fewer Emergencies in 2025 Impact Report
Alignment Healthcare's 2025 Impact Report highlights the success of its proactive care model, which has led to significant reductions in emergency room visits and hospital admissions. The report shows a commitment to improving member health through coordinated care and innovative technology. With 100% of plans rated 4 Stars or higher, Alignment continues to demonstrate high-quality performance in the Medicare Advantage sector.
Read more →-ALHC
May 18, 2026Alignment Healthcare to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
Alignment Healthcare, Inc. (NASDAQ: ALHC) will present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. The event will take place in Miami, Florida, at 10:40 a.m. EDT. A webcast of the presentation will be accessible on the company's investor relations website.
Read more →-ALHC
May 12, 2026▲ +7.1%on this news
Alignment Healthcare Strengthens Leadership Team to Support Long-Term Growth and Shareholder Value Creation Founder and CEO John Kao Assumes Additional Role as Chairman of the Board Orange, Calif.
Alignment Healthcare has announced key leadership changes to enhance its growth strategy. Founder and CEO John Kao will also serve as Chairman of the Board, ensuring continuity in leadership. Industry veterans Mark Kent and Shane Hochradel join the team in critical roles to strengthen the management structure and operational execution. These changes are designed to support the company's expansion and commitment to long-term shareholder value creation.
Read more →-ALHC
Apr 9, 2026Alignment Healthcare to Announce First Quarter 2026 Financial Results and Host Conference Call Thursday, April 30, 2026
Alignment Healthcare, Inc. (NASDAQ: ALHC) will announce its first quarter 2026 financial results on April 30, 2026, after market close. Following the announcement, a conference call will be held at 5 p.m. EDT to discuss the results. The company emphasizes its commitment to providing quality care for Medicare Advantage members.
Read more →-ALHC
Apr 1, 2026Alignment Healthcare to Present at the BofA Securities Health Care Conference 2026
Alignment Healthcare, Inc. (NASDAQ: ALHC) will present at the BofA Securities Health Care Conference 2026 in Las Vegas on May 13. The webcast of the presentation will be available on their investor relations website. The company is committed to providing high-quality, low-cost care for Medicare Advantage members.
Read more →-ALHC
Feb 23, 2026Alignment Healthcare to Present at the Leerink Partners Global Healthcare Conference
Alignment Healthcare, Inc. (NASDAQ: ALHC) announced its participation in the Leerink Partners Global Healthcare Conference, scheduled for March 10 in Miami, Florida. The presentation will be available via webcast on the company's investor relations website. Alignment Healthcare emphasizes its commitment to enhancing senior care through innovative services and technology.
Read more →-ALHC
Feb 5, 2026Alignment Healthcare to Announce Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call Thursday, Feb. 26, 2026
Alignment Healthcare, Inc. (NASDAQ: ALHC) will announce its fourth quarter and full-year 2025 financial results on February 26, 2026. Following the announcement, a conference call will be held at 5 p.m. EST to discuss the results. The company focuses on providing quality care for Medicare Advantage members through a unique care model.
Read more →-ALHC
Jan 21, 2026Alignment Healthcare Named to the 2026 Fortune World’s Most Admired Companies™ List for First Time
Alignment Healthcare has made its debut on the 2026 Fortune World's Most Admired Companies list, reflecting its strong reputation in the Health Care: Insurance and Managed Care category. This recognition comes five years after the company went public and highlights its commitment to senior care. CEO John Kao attributes this achievement to the team's dedication and innovative approach to Medicare Advantage.
Read more →-ALHC
Jan 20, 2026Alignment Health Appoints Adnan Mansour as Chief Digital Officer to Accelerate AI-Driven Growth and Technology Leadership
Alignment Health has appointed Adnan Mansour as Chief Digital Officer, effective January 19, 2026. Mansour, who previously held a senior role at Optum Insight, will focus on scaling the company's digital capabilities and enhancing its AI-powered AVA platform. This strategic move comes as Alignment Health experiences substantial growth in its Medicare Advantage membership.
Read more →-ALHC
Jan 8, 2024▲ +13.2%on this news
Legal Disclaimer Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Ac
Alhambra Health Care (ALHC) has reported a substantial growth in membership, achieving a 44% year-over-year increase with 155,500 members as of January 1, 2024. This growth primarily stems from effective market strategies, particularly in California, and successful operational execution during the Annual Enrollment Period. The company also anticipates reaching Adjusted EBITDA breakeven in 2024, supported by enhanced member engagement and the implementation of the AVA technology platform. Looking forward, ALHC expects favorable conditions in 2025, aided by ongoing improvements and strategic investments.
Read more →-ALHC
May 17, 2021ALIGNMENT HEALTHCARE REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS ORANGE, Calif. (
ALIGNMENT HEALTHCARE REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS ORANGE, Calif. (May 17, 2021) Alignment Healthcare, Inc. ( Alignment Healthcare or the Company ) (Nasdaq: ALHC), a mission-based, tech-enabled Medicare Advantage company, today reported financial results for its
Read more →-ALHC
Mar 30, 2021ALIGNMENT HEALTHCARE ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING ORANGE, Calif. (
ALIGNMENT HEALTHCARE ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING ORANGE, Calif. (March 30, 2021) Alignment Healthcare, Inc. ( Alignment Healthcare or the Company ) (Nasdaq: ALHC), a mission-based, tech-enabled Medicare Advantage company, today announced the closing of its init
Read more →Competitive Position
How ALHC ranks across every disease it competes inCompetitive Position is a premium feature
See how ALHC ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial